Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 8Breast Neoplasms 6Prostatic Neoplasms 5Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Lung Neoplasms 2Glioma 2Glioblastoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

venetoclax 1pembrolizumab 1niraparib 1ibrutinib 1encorafenib 1copanlisib 1capivasertib 1RNA-Seq 1Nivolumab 1Interleukin-2 1Gemtuzumab 1Fulvestrant 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Disease Progression × niraparib × Clear all
NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡